WASHINGTON — Almost immediately after beginning his Bethesda, Md., day job as the nation’s top cancer researcher, Ned Sharpless built a roughly 7-mile detour into his weekly routine: a sojourn to the Food and Drug Administration campus for a pickup basketball game.

Whether or not the networking was intentional, Sharpless will soon be spending far more time with the FDA oncologists who once broke his finger. When Scott Gottlieb steps down after a nearly two-year tenure next month, Sharpless will take the helm of that agency, at least in the short term.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The Revolving Door keeps spinning. Chemotherapy Rules. Pharma gets its Trojan Horse moved from the NCI to the FDA. This whole Medical Cartel needs blasting apart. Keep a watchful eye on Gottlieb.

  • Nice that Sharpless is keeping fit with some of his staffers, but what is he doing to network with female staffers, most of whom won’t play pickup basketball, I assume??

  • The NCI could get a real director now, the FDA will continue the war against tobacco. The cancer patients always loose..

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy